These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36919343)

  • 1. Telomerase inhibition in malignant gliomas: a systematic review.
    D'Alessandris QG; Battistelli M; Pennisi G; Offi M; Martini M; Cenci T; Falchetti ML; Lauretti L; Olivi A; Pallini R; Montano N
    Expert Rev Mol Med; 2023 Mar; 25():e10. PubMed ID: 36919343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
    Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S
    Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.
    Bollam SR; Berens ME; Dhruv HD
    Curr Neurol Neurosci Rep; 2018 Mar; 18(4):15. PubMed ID: 29525892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter.
    Komata T; Koga S; Hirohata S; Takakura M; Germano IM; Inoue M; Kyo S; Kondo S; Kondo Y
    Int J Oncol; 2001 Nov; 19(5):1015-20. PubMed ID: 11605003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells.
    Komata T; Kondo Y; Kanzawa T; Ito H; Hirohata S; Koga S; Sumiyoshi H; Takakura M; Inoue M; Barna BP; Germano IM; Kyo S; Kondo S
    Hum Gene Ther; 2002 Jun; 13(9):1015-25. PubMed ID: 12067435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461.
    Li G; Shen J; Cao J; Zhou G; Lei T; Sun Y; Gao H; Ding Y; Xu W; Zhan Z; Chen Y; Huang H
    J Exp Clin Cancer Res; 2018 Apr; 37(1):78. PubMed ID: 29631594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase activity and hTERT mRNA expression in glial tumors.
    Boldrini L; Pistolesi S; Gisfredi S; Ursino S; Ali G; Pieracci N; Basolo F; Parenti G; Fontanini G
    Int J Oncol; 2006 Jun; 28(6):1555-60. PubMed ID: 16685456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter.
    Komata T; Kondo Y; Kanzawa T; Hirohata S; Koga S; Sumiyoshi H; Srinivasula SM; Barna BP; Germano IM; Takakura M; Inoue M; Alnemri ES; Shay JW; Kyo S; Kondo S
    Cancer Res; 2001 Aug; 61(15):5796-802. PubMed ID: 11479218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
    Masui K; Komori T; Kato Y; Masutomi K; Ichimura K; Ogasawara S; Kaneko MK; Oki H; Suzuki H; Nitta M; Maruyama T; Muragaki Y; Kawamata T; Sawada T; Shibata N
    Biomed Res Int; 2018; 2018():7945845. PubMed ID: 29693015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningiomas, dicentric chromosomes, gliomas, and telomerase activity.
    Carroll T; Maltby E; Brock I; Royds J; Timperley W; Jellinek D
    J Pathol; 1999 Aug; 188(4):395-9. PubMed ID: 10440750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of telomerase gene hTERT polymorphism and malignant gliomas.
    Carpentier C; Lejeune J; Gros F; Everhard S; Marie Y; Kaloshi G; Laigle-Donadey F; Hoang-Xuan K; Delattre JY; Sanson M
    J Neurooncol; 2007 Sep; 84(3):249-53. PubMed ID: 17410334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
    Stögbauer L; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
    Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y
    Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase as a therapeutic target in glioblastoma.
    Aquilanti E; Kageler L; Wen PY; Meyerson M
    Neuro Oncol; 2021 Dec; 23(12):2004-2013. PubMed ID: 34473298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma.
    Fan HC; Chen CM; Chi CS; Tsai JD; Chiang KL; Chang YK; Lin SZ; Harn HJ
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30625996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.